
Study
Treatment Yes No
Control Yes No
Odds ratio with 95% CI
Weight (%)
1-3 Month
Palmer et al, 2023 5 13 2 10 1.93 [0.31, 12.07] 2.22
Krishnan et al, 2023_Text 6 47 1 25 3.19 [0.36, 28.00] 1.60
Krishnan et al, 2023_Text_Consult 15 38 2 25 4.93 [1.04, 23.47] 3.03
Heterogeneity: τ² = 0.00, I² = 0.00%, H² = 1.00 3.29 [1.16, 9.35]
Test of θi = θj: Q(2) = 0.59, p = 0.75
4-6 Month
Caponnetto et al, 2023 24 46 12 58 2.53 [1.14, 5.60] 10.15
Heterogeneity: τ² = 0.00, I² = .%, H² = . 2.53 [1.14, 5.60]
Test of θi = θj: Q(0) = 0.00, p = .
7-9 Month
Graham et al, 2021 328 645 298 696 1.19 [0.98, 1.43] 45.47
Heterogeneity: τ² = 0.00, I² = .%, H² = . 1.19 [0.98, 1.43]
Test of θi = θj: Q(0) = 0.00, p = .
10-12 Month
Martinez et al, 2021_Target 97 284 21 90 1.46 [0.86, 2.47] 18.79
Martinez et al, 2021_Generic 98 253 21 90 1.65 [0.97, 2.80] 18.73
Heterogeneity: τ² = 0.00, I² = 0.00%, H² = 1.00 1.55 [1.07, 2.25]
Test of θi = θj: Q(1) = 0.10, p = 0.75
Overall 1.52 [1.15, 2.01]
Heterogeneity: τ² = 0.04, I² = 26.53%, H² = 1.36
Test of θi = θj: Q(6) = 8.17, p = 0.23
Test of group differences: Qb(3) = 7.48, p = 0.06
1/2
1
2
4
8
16
Random-effects DerSimonian–Laird model

A


Study
Treatment Yes No
Control Yes No
Odds ratio with 95% CI
Weight (%)
Digital Intervention
Graham et al, 2021 328 645 298 696 1.19 [0.98, 1.43] 45.47
Krishnan et al, 2023_Text 6 47 1 25 3.19 [0.36, 28.00] 1.60
Krishnan et al, 2023_Text_Consult 15 38 2 25 4.93 [1.04, 23.47] 3.03
Heterogeneity: τ² = 0.41, I² = 49.02%, H² = 1.96 1.95 [0.73, 5.22]
Test of θi = θj: Q(2) = 3.92, p = 0.14
Pharmacological Intervention
Palmer et al, 2023 5 13 2 10 1.93 [0.31, 12.07] 2.22
Caponnetto et al, 2023 24 46 12 58 2.53 [1.14, 5.60] 10.15
Heterogeneity: τ² = 0.00, I² = 0.00%, H² = 1.00 2.42 [1.17, 5.02]
Test of θi = θj: Q(1) = 0.07, p = 0.79
Educational Intervention
Martinez et al, 2021_Target 97 284 21 90 1.46 [0.86, 2.47] 18.79
Martinez et al, 2021_Generic 98 253 21 90 1.65 [0.97, 2.80] 18.73
Heterogeneity: τ² = 0.00, I² = 0.00%, H² = 1.00 1.55 [1.07, 2.25]
Test of θi = θj: Q(1) = 0.10, p = 0.75
Overall 1.52 [1.15, 2.01]
Heterogeneity: τ² = 0.04, I² = 26.53%, H² = 1.36
Test of θi = θj: Q(6) = 8.17, p = 0.23
Test of group differences: Qb(2) = 1.21, p = 0.55
1/2
1
2
4
8
16
Random-effects DerSimonian–Laird model

B



C

Supplementary file 2: sub grouped analysis of Vaping Cessation Interventions on 7-day Point Prevalence of Abstinence based on duration (A) type of interventions (B) and subgroup of -day Point Prevalence of Abstinence measurements within studies (C).